{"id":410063,"date":"2021-01-07T02:12:03","date_gmt":"2021-01-07T07:12:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410063"},"modified":"2021-01-07T02:12:03","modified_gmt":"2021-01-07T07:12:03","slug":"oncozenge-announces-issue-of-european-patent-related-to-bupizenge","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/","title":{"rendered":"OncoZenge announces issue of European Patent related to BupiZenge\u00ae"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">STOCKHOLM<\/span>, <span class=\"xn-chron\">Jan. 7, 2021<\/span> \/PRNewswire\/ &#8212; <b>OncoZenge AB (publ), Moberg Pharma&#8217;s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge<sup>\u00ae<\/sup>, currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032.<\/b><\/p>\n<p>The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients. BupiZenge<sup>\u00ae<\/sup> has previously been granted patents with a similar scope in <span class=\"xn-location\">the United States<\/span> and <span class=\"xn-location\">Canada<\/span>.<\/p>\n<p>&#8220;<i>The patent significantly strengthens the intellectual property for BupiZenge<\/i><sup>\u00ae<\/sup><i>\u00a0in <span class=\"xn-location\">Europe<\/span><\/i>&#8220;, <span class=\"xn-person\">Pirkko Tamsen<\/span>, CEO of OncoZenge comments. &#8220;<i>It protects the use of BupiZenge<\/i><sup>\u00ae<\/sup><i>\u00a0in all relevant indications for treatment of pain in the oral cavity<\/i>&#8220;.<\/p>\n<p>\n        <b>About Oral Mucositis and BupiZenge<sup>\u00ae<\/sup><\/b>\n      <\/p>\n<p>Globally, around 5 million people suffer from Oral mucositis (&#8220;OM&#8221;) after cancer treatment. OM is an inflammation of the mucous membranes in the mouth and throat, which results in painful ulcers. OM is considered the most debilitating side effect of radiation therapy and chemotherapy and commonly occurs. After radiation therapy in the head and neck region, 90 percent of patients develop OM, and of the patients who are treated with chemotherapy around 30 percent are affected. OM causes severe pain, difficulty to swallow and talk, and can lead to interruptions in cancer treatment as well as increased health care costs. <\/p>\n<p>The BupiZenge<sup>\u00ae<\/sup> technology encompasses novel lozenge formulations of bupivacaine, a local anesthetic with a well-established long acting effect, currently available on the market for other indications as an injectable. In a previous phase 2 study on cancer patients, BupiZenge<sup>\u00ae<\/sup> has demonstrated statistically significant pain relief in the oral cavity and throat; the pain level in the mouth was reduced by 50 percent. compared to the current treatment. <\/p>\n<p>\n        <b>CONTACT: <\/b>\n      <\/p>\n<p>\n        <b>For additional information, please contact:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Pirkko Tamsen<\/span><br \/>\n        <br \/>CEO OncoZenge <br \/>telephone: +46\u00a0760 09 84 99<br \/>e-mail:\u00a0<a target=\"_blank\" href=\"mailto:pirkko.tamsen@oncozenge.se\" rel=\"nofollow noopener noreferrer\">pirkko.tamsen@oncozenge.se<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Anna Ljung<\/span><br \/>\n        <br \/>CEO <span class=\"xn-person\">Moberg Pharma<\/span><br \/>telephone: +46\u00a0707 66 60 30<br \/>e-mail:\u00a0<a target=\"_blank\" href=\"mailto:anna.ljung@mobergpharma.se\" rel=\"nofollow noopener noreferrer\">anna.ljung@mobergpharma.se<\/a><\/p>\n<p>\n        <b>About this information<\/b><br \/>\n        \n      <\/p>\n<p>The information was submitted for publication, through the agency of the contact persons set out above, at <span class=\"xn-chron\">8.00 a.m. CET<\/span> on <span class=\"xn-chron\">January 7<\/span><sup>th<\/sup>, 2021.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3028543-1&amp;h=2623462447&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3028543-1&amp;h=2195391246&amp;u=https%3A%2F%2Fnews.cision.com%2Fmoberg-pharma%2Fr%2Foncozenge-announces-issue-of-european-patent-related-to-bupizenge-%2Cc3264095&amp;a=https%3A%2F%2Fnews.cision.com%2Fmoberg-pharma%2Fr%2Foncozenge-announces-issue-of-european-patent-related-to-bupizenge-%2Cc3264095\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/moberg-pharma\/r\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge-,c3264095<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3028543-1&amp;h=2066377373&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F1662%2F3264095%2F1356111.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F1662%2F3264095%2F1356111.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/1662\/3264095\/1356111.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">OncoZenge announces issue of European Patent related to BupiZenge\u00ae<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO39842&amp;sd=2021-01-07\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge-301202572.html\">http:\/\/www.prnewswire.com\/news-releases\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge-301202572.html<\/a><\/p>\n<p>SOURCE  Moberg Pharma<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO39842&amp;Transmission_Id=202101070208PR_NEWS_USPR_____IO39842&amp;DateId=20210107\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire STOCKHOLM, Jan. 7, 2021 \/PRNewswire\/ &#8212; OncoZenge AB (publ), Moberg Pharma&#8217;s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge\u00ae, currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032. The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients. BupiZenge\u00ae has previously been granted patents with a similar scope in the United States and Canada. &#8220;The patent significantly &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OncoZenge announces issue of European Patent related to BupiZenge\u00ae&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410063","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OncoZenge announces issue of European Patent related to BupiZenge\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncoZenge announces issue of European Patent related to BupiZenge\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Jan. 7, 2021 \/PRNewswire\/ &#8212; OncoZenge AB (publ), Moberg Pharma&#8217;s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge\u00ae, currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032. The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients. BupiZenge\u00ae has previously been granted patents with a similar scope in the United States and Canada. &#8220;The patent significantly &hellip; Continue reading &quot;OncoZenge announces issue of European Patent related to BupiZenge\u00ae&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T07:12:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO39842&amp;sd=2021-01-07\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OncoZenge announces issue of European Patent related to BupiZenge\u00ae\",\"datePublished\":\"2021-01-07T07:12:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/\"},\"wordCount\":427,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO39842&amp;sd=2021-01-07\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/\",\"name\":\"OncoZenge announces issue of European Patent related to BupiZenge\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO39842&amp;sd=2021-01-07\",\"datePublished\":\"2021-01-07T07:12:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO39842&amp;sd=2021-01-07\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO39842&amp;sd=2021-01-07\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncoZenge announces issue of European Patent related to BupiZenge\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncoZenge announces issue of European Patent related to BupiZenge\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/","og_locale":"en_US","og_type":"article","og_title":"OncoZenge announces issue of European Patent related to BupiZenge\u00ae - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Jan. 7, 2021 \/PRNewswire\/ &#8212; OncoZenge AB (publ), Moberg Pharma&#8217;s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge\u00ae, currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032. The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients. BupiZenge\u00ae has previously been granted patents with a similar scope in the United States and Canada. &#8220;The patent significantly &hellip; Continue reading \"OncoZenge announces issue of European Patent related to BupiZenge\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T07:12:03+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO39842&amp;sd=2021-01-07","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OncoZenge announces issue of European Patent related to BupiZenge\u00ae","datePublished":"2021-01-07T07:12:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/"},"wordCount":427,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO39842&amp;sd=2021-01-07","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/","name":"OncoZenge announces issue of European Patent related to BupiZenge\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO39842&amp;sd=2021-01-07","datePublished":"2021-01-07T07:12:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO39842&amp;sd=2021-01-07","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO39842&amp;sd=2021-01-07"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncozenge-announces-issue-of-european-patent-related-to-bupizenge\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OncoZenge announces issue of European Patent related to BupiZenge\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410063"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410063\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}